Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Glioma 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Cholangiocarcinoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Gemcitabine 22Cisplatin 17durvalumab 12lenvatinib 11Oxaliplatin 11pembrolizumab 6Liver Transplantation 4Leucovorin 4Floxuridine 4tislelizumab 3Taxes 3Nivolumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Fluorouracil 3Drug Therapy 3Capecitabine 3Biopsy 3Albumin-Bound Paclitaxel 3tremelimumab 2pemigatinib 2olaparib 2ivosidenib 2irinotecan sucrosofate 2apatinib 2Specimen Handling 2Injections 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cholangiocarcinoma × olutasidenib × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡